Temsirolimus-resistant, checkpoint-deficient, homeostatic cytokine-responsive autologous TH1/TC1 cells for therapy of relapsed, refractory multiple myeloma (RRMM)

Felizardo, Tania C.; Limas, S. Mosquera; Zhu, Nengping; Bushera, H.; Glass, Daniel; Hari, Parameswaran; Dhakal, Binod; Fowler, Daniel H.

doi:10.1016/s1465324921004011

Cytotherapy

2021

DOI: 10.1016/s1465324921004011

|View full text |Cite

Temsirolimus-resistant, checkpoint-deficient, homeostatic cytokine-responsive autologous TH1/TC1 cells for therapy of relapsed, refractory multiple myeloma (RRMM)

Tania C. Felizardo¹,

S. Mosquera Limas²,

Nengping Zhu³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Other1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Background Polyclonal RAPA-201 is enriched for central-memory, polarized to Th1/Tc1, and rendered immune checkpointdeficient and homeostatic cytokine-responsive. 1 RAPA-201 safely mediates disease remissions in multiple myeloma when administered after lymphodepleting conditioning. 2 RAPA-201 is also resistant to chemotherapy, including carboplatin (CBCCA), paclitaxel (PTX), and topotecan (Park JH et al, separate abstract submitted to SITC 2023).…”

mentioning

confidence: 99%

723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning

Gutierrez,

Donato,

Reich-Slotky

et al. 2023

Regular and Young Investigator Award Abstracts

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning

Gutierrez,

Donato,

Reich-Slotky

et al. 2023

Regular and Young Investigator Award Abstracts

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Temsirolimus-resistant, checkpoint-deficient, homeostatic cytokine-responsive autologous TH1/TC1 cells for therapy of relapsed, refractory multiple myeloma (RRMM)

Cited by 1 publication

References 0 publications

723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning

723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning

Contact Info

Product

Resources

About